Search Results

Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal neuralgia and type 1 diabetes.

Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, announced the appointment of Katherine Eade to the position of Chief Legal Officer.

Kriya Therapeutics, Inc. announced three presentations at the Association for Research in Vision and Ophthalmology Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.

Kriya Therapeutics, Inc. (“Kriya”), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced six presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which will be held May 7 to 11, 2024 in Baltimore, MD.

Kriya Therapeutics, Inc., (Kriya) today announced its gene therapy program for thyroid eye disease (TED), a debilitating autoimmune condition resulting in proptosis and diplopia, medical terms describing bulging of the eyes and double vision respectively, due to inflammation of the muscles and fat tissue behind the eye.